Cleveland BioLabs, Inc.  

(Public, NASDAQ:CBLI)   Watch this stock  
Find more results for CBLI
0.278
+0.008 (2.96%)
Dec 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.27 - 0.29
52 week 0.26 - 1.27
Open 0.27
Vol / Avg. 0.00/272,412.00
Mkt cap 15.89M
P/E     -
Div/yield     -
EPS -0.19
Shares 57.15M
Beta 1.64
Inst. own 6%
Nov 5, 2014
Q3 2014 Cleveland Biolabs Inc Earnings Call
Nov 5, 2014
Q3 2014 Cleveland Biolabs Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1111.86% -237.15%
Operating margin -828.35% -271.88%
EBITD margin - -260.36%
Return on average assets -133.69% -86.20%
Return on average equity - -
Employees 44 -
CDP Score - -

Address

73 High St
BUFFALO, NY 14203-1149
United States - Map
+1-716-8496810 (Phone)
+1-716-8496820 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company with a focus on oncology drug development. The Company�s lead drug candidate CBLB502 is developed for dual indications under the United States Food & Drug Administration's (FDA's) Animal Efficacy Rule, commonly referred to as the Animal Rule, as a radiation countermeasure, and under the FDA's traditional drug approval pathway as an anti-cancer agent and an oncology supportive care therapy. As of December 31, 2011, the Company had nine product candidates in its pipeline that are developed directly by the Company and its majority owned subsidiaries. The products include CBLB502, CBLB502, CBLB502, CBLB612, CBLC102, CBLC137, Revercom, Mobilan, Arkil, Antimycon, and Xenomycins. As of December 31, 2011, the Company had an approximately 75.8% ownership interest in Incuron, LLC (Incuron).As of December 31, 2011, the Company had an ownership stake of approximately 54.6% in Panacela Labs, Inc. (Panacela).

Officers and directors

Yakov N. Kogan Ph.D. Chief Executive Officer, Director
Age: 41
Bio & Compensation  - Reuters
C. Neil Neil Lyons CPA Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Andrei V. Gudkov Ph.D. Chief Scientific Officer, Director
Age: 57
Bio & Compensation  - Reuters
James J. Antal CPA Independent Director
Age: 63
Bio & Compensation  - Reuters
Julia R. Brown Independent Director
Age: 66
Bio & Compensation  - Reuters
Anthony J. Principi J.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Randy S. Saluck J.D. Independent Director
Age: 48
Bio & Compensation  - Reuters